Turnover Talk: Current Treatment Decisions for Front Line Ovarian Cancer
Discussion of maintenance therapy with PARPi, or bevacizumab, and improvement in progression free survival after front line treatment for advanced high grade epithelial ovarian cancer
Category
  • Turnover Talks
  • Ovary
  • PARPi
Format
Credits
Turnover Talk: Molecular Testing and Patient Selection in Ovarian Cancer
A brief discussion of homologous recombination deficiency, loss of heterozygosity, and molecular markers in ovarian cancer, and how this can guide therapy.
Category
  • Turnover Talks
  • Ovary
  • Genetics
  • Targeted Therapy
Format
  • On-Demand
Credits
Turnover Talk: RRSO in Mutation Carriers
Short discussion of genetic mutation carriers and recommendations for risk reducing salpingo-oophorectomy.
Category
  • Turnover Talks
  • Ovary
  • Genetics
Format
  • On-Demand
Credits